



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com



Contact: Dana Wormer
GenomeQuest, Inc.
(215) 888-0960
dana.wormer@genomequest.com

GENEGO ANNOUNCES INTEGRATION WITH GENOMEQUEST FOR PATHWAY ANALYSIS OF NEXT GENERATION SEQUENCING DATA

St Joseph, Michigan, October 7th, 2010 - GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, announced today that they have integrated GenomeQuest's Sequence Data Management (SDM) platform with GeneGo's MetaCore and MetaDrug.

Using GenomeQuest's interactive analysis, scientists who have drilled down to a list of particular genes of interest (hundreds of millions of reads, to thousands of expressed genes, to dozens or more of particular genes of interest) can now seamlessly pass that gene list along with their associated expression values (RPKM) to the GeneGo suite of pathway analysis software tools.

"The ability to analyze hundreds of datasets, reducing millions of reads down to a shorter list of particular genes of interest, and then being able to visualize where those genes are active in specific (potentially disease-related) pathways, is a significant accomplishment in the integration of omics software offerings. Scientists will be able to quickly focus on their scientific questions, rather than manipulating large reads datasets and lists of thousands of genes. We believe this will enhance discovery throughout the genomics and proteomics research pipelines," said Dr. Don Gregory, GenomeQuest's Director of Field Application Scientists.

"This integration will allow our joint customers to seamlessly work with NGS data in the context of pathways", said Julie Bryant VP of business development for GeneGo. "The integrated workflows will lead our users from raw sequence runs to functional hypothesis generation of drug targets and biomarkers. With NGS data picking up steam in translational medicine and individual healthcare, this integration will help us to leverage our unique disease pathology maps (causal models) developed in our MetaMiner programs in oncology, CNS, metabolic, respiratory diseases and other therapeutic areas."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscoveryTM platform allows an integration and expert

analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.3™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.3™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About GenomeQuest

GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. Over 160 leading health and agriculture companies use GenomeQuest for mission-critical work, including nine of the top ten pharmaceuticals. The company's core technology is the GQ-Engine -- a database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.

For more information, please visit the company's web site at www.genomequest.com.